CA2384018C - Muscarinic antagonists - Google Patents
Muscarinic antagonists Download PDFInfo
- Publication number
- CA2384018C CA2384018C CA002384018A CA2384018A CA2384018C CA 2384018 C CA2384018 C CA 2384018C CA 002384018 A CA002384018 A CA 002384018A CA 2384018 A CA2384018 A CA 2384018A CA 2384018 C CA2384018 C CA 2384018C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- etoac
- compounds
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*=C(*C(CC1)CCN1C1CCNCC1)C=C[C@@](*)S(c1ccccc1)([O-])=* Chemical compound C*=C(*C(CC1)CCN1C1CCNCC1)C=C[C@@](*)S(c1ccccc1)([O-])=* 0.000 description 2
- SIJBDWPVNAYVGY-UHFFFAOYSA-N CC1(C)OCCO1 Chemical compound CC1(C)OCCO1 SIJBDWPVNAYVGY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40139199A | 1999-09-22 | 1999-09-22 | |
| US09/401,391 | 1999-09-22 | ||
| PCT/US2000/018358 WO2001021590A1 (en) | 1999-09-22 | 2000-07-05 | Muscarinic antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2384018A1 CA2384018A1 (en) | 2001-03-29 |
| CA2384018C true CA2384018C (en) | 2010-01-12 |
Family
ID=23587566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002384018A Expired - Fee Related CA2384018C (en) | 1999-09-22 | 2000-07-05 | Muscarinic antagonists |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1214299B1 (enExample) |
| JP (1) | JP2003509494A (enExample) |
| CN (1) | CN1167682C (enExample) |
| AR (1) | AR025459A1 (enExample) |
| AT (1) | ATE264301T1 (enExample) |
| AU (1) | AU5786300A (enExample) |
| CA (1) | CA2384018C (enExample) |
| CO (1) | CO5180624A1 (enExample) |
| DE (1) | DE60009931T2 (enExample) |
| ES (1) | ES2215055T3 (enExample) |
| HK (1) | HK1043590A1 (enExample) |
| MX (1) | MXPA02003136A (enExample) |
| PE (1) | PE20010649A1 (enExample) |
| WO (1) | WO2001021590A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| CN1301972C (zh) * | 2001-10-10 | 2007-02-28 | 先灵公司 | 作为毒覃碱拮抗剂的哌啶化合物 |
| JPWO2004069828A1 (ja) * | 2003-02-04 | 2006-05-25 | 三菱ウェルファーマ株式会社 | ピペリジン化合物およびその医薬用途 |
| EP2533645B1 (en) | 2010-02-09 | 2016-07-27 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| JP6478923B2 (ja) | 2013-02-07 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート |
| CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
| EP2968237A4 (en) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| CN107810002B (zh) | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
| HK1253029A1 (zh) | 2015-11-06 | 2019-06-06 | Neurocrine Biosciences, Inc. | 作为毒蕈碱性受体4(m4)拮抗剂用於治疗神经系统疾病的n-[2-(1-苄基哌啶-4-基)乙基]-4-(吡嗪-2-基)-哌嗪-1-甲酰胺衍生物及相关化合物 |
| EP4069367B1 (en) | 2019-12-06 | 2024-05-15 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691323A (en) * | 1995-05-12 | 1997-11-25 | Merck & Co., Inc. | Muscarine antagonists |
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| DE69919171T2 (de) * | 1998-06-30 | 2005-08-04 | Schering Corp. | Muskarin-rezeptor antagonisten |
| US6066636A (en) * | 1998-06-30 | 2000-05-23 | Schering Corporation | Muscarinic antagonists |
-
2000
- 2000-07-05 ES ES00943386T patent/ES2215055T3/es not_active Expired - Lifetime
- 2000-07-05 WO PCT/US2000/018358 patent/WO2001021590A1/en not_active Ceased
- 2000-07-05 HK HK02105117.5A patent/HK1043590A1/zh unknown
- 2000-07-05 DE DE60009931T patent/DE60009931T2/de not_active Expired - Lifetime
- 2000-07-05 CA CA002384018A patent/CA2384018C/en not_active Expired - Fee Related
- 2000-07-05 JP JP2001524970A patent/JP2003509494A/ja active Pending
- 2000-07-05 AT AT00943386T patent/ATE264301T1/de not_active IP Right Cessation
- 2000-07-05 AU AU57863/00A patent/AU5786300A/en not_active Abandoned
- 2000-07-05 CN CNB008130795A patent/CN1167682C/zh not_active Expired - Fee Related
- 2000-07-05 MX MXPA02003136A patent/MXPA02003136A/es unknown
- 2000-07-05 EP EP00943386A patent/EP1214299B1/en not_active Expired - Lifetime
- 2000-08-31 PE PE2000000890A patent/PE20010649A1/es not_active Application Discontinuation
- 2000-08-31 AR ARP000104540A patent/AR025459A1/es unknown
- 2000-08-31 CO CO00065610A patent/CO5180624A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2384018A1 (en) | 2001-03-29 |
| HK1043590A1 (zh) | 2002-09-20 |
| AR025459A1 (es) | 2002-11-27 |
| ES2215055T3 (es) | 2004-10-01 |
| AU5786300A (en) | 2001-04-24 |
| JP2003509494A (ja) | 2003-03-11 |
| EP1214299B1 (en) | 2004-04-14 |
| DE60009931T2 (de) | 2005-04-07 |
| DE60009931D1 (de) | 2004-05-19 |
| CN1374949A (zh) | 2002-10-16 |
| ATE264301T1 (de) | 2004-04-15 |
| CN1167682C (zh) | 2004-09-22 |
| PE20010649A1 (es) | 2001-06-19 |
| WO2001021590A1 (en) | 2001-03-29 |
| CO5180624A1 (es) | 2002-07-30 |
| EP1214299A1 (en) | 2002-06-19 |
| MXPA02003136A (es) | 2002-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6294554B1 (en) | Muscarinic antagonists | |
| EP1343760B1 (en) | Muscarinic antagonists | |
| US6288068B1 (en) | Muscarinic antagonists | |
| CA2263167C (en) | Ether muscarinic antagonists | |
| US5977138A (en) | Ether muscarinic antagonists | |
| CA2259655C (en) | 1,4-di-sustituted piperidines as muscarinic antagonists | |
| US4289772A (en) | 1-Piperidinophthalazines as cardiac stimulants | |
| AU756484B2 (en) | Muscarinic antagonists | |
| CA2384018C (en) | Muscarinic antagonists | |
| SK15082002A3 (sk) | Derivát pyridín-1-oxidu a spôsob jeho transformácie na farmaceuticky účinné zlúčeniny | |
| JP3269574B2 (ja) | メタノアントラセン化合物、これを含有する神経精神障害を治療するための調剤学的組成物、およびこの化合物を製造するための方法および中間体 | |
| RS54248B1 (sr) | Nova jedinjenja kao ligandi histamin h3 receptora | |
| NO791648L (no) | Fremgangsmaate ved fremstilling av nye kinazolinderivater | |
| Rádl et al. | Synthesis and analgesic activity of some quinazoline analogs of anpirtoline | |
| MXPA99001500A (en) | Ether muscarinic antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |